The development of a safe and reproducible gene delivery system is an essential step toward the clinical application of the hydrodynamic gene delivery (HGD) method. For this purpose, we have developed a novel electric power-driven injection system called the HydroJector-EM, which can replicate various time-pressure curves preloaded into the computer program before injection. The assessment of the reproducibility and safety of gene delivery system in vitro and in vivo demonstrated the precise replication of intravascular time-pressure curves and the reproducibility of gene delivery efficiency. The highest level of luciferase expression (272 pg luciferase per mg of proteins) was achieved safely using the time-pressure curve, which reaches 30 mm Hg in 10 s among various curves tested. Using this curve, the sustained expression of a therapeutic level of human factor IX protein (4500 ng ml À 1 ) was maintained for 2 months after the HGD of the pBS-HCRHP-FIXIA plasmid. Other than a transient increase in liver enzymes that recovered in a few days, no adverse events were seen in rats. These results confirm the effectiveness of the HydroJector-EM for reproducible gene delivery and demonstrate that long-term therapeutic gene expression can be achieved by automatic computer-controlled hydrodynamic injection that can be performed by anyone.
INTRODUCTION
Gene therapy has shown promising results in treating major disease, including cancer, cardiovascular diseases and hemophilia, 1 and the popularity of gene therapy for these diseases continues to grow. Among the various methods of gene transfer, hydrodynamic gene delivery (HGD) was first reported to be a simple and effective gene delivery method for the mouse liver in 1999. 2, 3 Since then, HGD has been extensively studied and used in small animals for various types of gene delivery research, including gene expression, gene functional analysis, gene regulation, drug metabolism, establishment of animal models, drug discovery, viral vectors and nanoparticles (for recent reviews, see Suda and Liu, 4 Herweijer and Wolff, 5 Kamimura and Liu, 6 Kamimura et al. 7 and Bonamassa et al. 8 ). The method of HGD consists of the rapid and pressurized injection of a large amount of isotonic DNA solution into a target organ via vessels. [9] [10] [11] [12] However, traditional HGD technology has not been directly applied to humans owing to safety issues related to an unexpected large volume and high intravascular pressure during gene delivery, and difficulty in maintaining reproducibility due to the variability of responsiveness to the pressure in target organs.
In the past decade, our team and others have improved several aspects of the HGD procedure in addressing these issues. First, a catheter-based procedure was included to reduce injection volume and achieve site-specific DNA delivery. [13] [14] [15] [16] [17] [18] Eastman et al. 13 reported successful isolated liver-targeted HGD in rabbits with a volume of 15 ml kg
; Yoshino et al.
14 reported single-lobespecific gene delivery in pigs using catheterization and occlusion of the portal vein (PV); and Alino et al. 15 reported successful gene delivery of the human a-1 antitrypsin gene by catheterization. Fabre et al. 16 isolated the liver by double occlusions in the inferior vena cava (IVC) and performed whole liver-targeted HGD from the IVC. 16 A recent report from Alino's group 19 demonstrated the efficacy of this procedure in ex vivo human liver segments. 19 Second, we developed a CO 2 -pressurized injector, called the 'HydroJector', for a sustained injection power for the maintenance of injection parameters. 20 This injector cleared the problem of a sustained flow rate injection by traditional manual hydrodynamic injection or simple pump injection associated with high variability in gene expression in vivo due to resistance in the area. 14 We recently showed that these two improvements yield a catheterbased regional liver lobe-specific HGD by inserting the catheter into each hepatic vein followed by the CO 2 -pressurized injection of gene delivery. We called this development the 'Image-guided regional HGD', and it achieved 100-to 1000-fold improved gene expression compared with previous reports, 14, 15 with a volume of 1% body weight (BW) that was 10-fold less than was used in those reports. Moreover, the sequential injection of multiple lobes can be safely performed with this procedure. 17 We also reported the applicability of this procedure to swine muscle. 18 While carefully studying the physiological data and gene delivery efficiency of 'Image-guided regional HGD', we determined that the level of gene expression in the liver lobe after HGD depends on the intravascular pressure upon injection, which is affected by various factors, including placement of the catheter, leakage to the IVC, intravenous anastomosis, balloon inflation and differences in histological structures such as fibrotic tissue. 17 For example, in swine liver, sustained injection power of 300 psi for 15 s resulted in luciferase activity of 10 7 relative light units (RLU) per mg of  proteins in the right medial, left medial and left lateral lobes, and  10 4 level in the right lateral lobe. This 1000-fold difference was proven to be due to the anatomically larger number of leakage pathways to IVC of the solution from the right lateral lobe. 17 The time-pressure curve during these injections showed a sustained peak pressure of 75 mm Hg over the entire injection period in area achieved 10 7 level and an irregularly shaped curve reaching a peak pressure of 70 mm Hg in 5 s and declining slowly thereafter for 10 s was seen in 10 4 area. These results indicate that the timepressure curve upon the injection is significantly related to gene delivery efficiency and reproducibility. 17, 18 Therefore, we realized that the remaining challenge for the use of the catheter-based 'Image-guided regional HGD' procedure in humans is to control the time-pressure curves for the precise reproducibility and controllability of gene delivery. For this purpose, we have developed a novel electric power-driven hydrodynamic injection system, called the HydroJector-EM, and evaluated its gene delivery efficiency, reproducibility and safety in this study. The significant advantage of this injector is its precise replication of time-pressure curves that have been preloaded into the program for various targets by flexibly controlling the injection power. This has never been achieved with a manual injection or a simple pump. Furthermore, the HydroJector-EM consists of clinically approved parts and disposable products, such as syringes and injection tubes, for future clinical applications. Here we report for the first time the precise reproducibility and controllability of safe and efficient HGD using our new system. Our long-term study demonstrated sustained therapeutic gene expression of human factor IX in rats. The results indicate that anyone can achieve safe, efficient and therapeutic HGD using this new system; thus, the clinical applications of HGD procedures can be realized.
RESULTS
A major obstacle in developing clinically applicable HGD technology is precise reproducibility of gene delivery and safety of the procedure. The HydroJector-EM developed in this study can precisely replicate time-pressure curves that have been preloaded into the program and reproduces safe and effective gene delivery.
Development of the new gene injector A major advantage of the HydroJector-EM is the flexible and fine computer control of the injection power to replicate precisely the programmed time-pressure curves for safe, efficient and reproducible gene delivery, which is unable to be achieved by the manual or the simple pump. In this new system, firstly we preload time-pressure curves before injection ( Figure 1a, Step 1). Then, the electric power-driven injector pushes a sterilized syringe and injects its solution into the target region ( Figure 1a, Step 2). The actual pressure in the target region during injection is transmitted to the programmed computer every 0.05 s through a pressure sensor placed in the vasculature connected to the target organ, such as PV in the liver, and amplifier ( Figure 1a, Step 3). The system employs a pulse-width modulation control according to the pressure, and a program stored in the computer moves the syringe set in the injector and produces a preloaded timepressure curve ( Figure 1a , Step 4) . If the actual pressure in the region is lower than the preloaded pressure curve, it sends the signal for a larger output to increase the pressure inside by a faster injection, and vice versa. This is the major difference from the previously developed CO 2 -pressurized injector that provides sustained injection power output. To assess the controllability of this injector in vitro, various pressure curves-exponential (Figure 1b) , convex (Figure 1c ), stepwise ( Figure 1d ) and frequent spike (Figure 1e ) pressure patterns-were preloaded into the system (gray solid lines in Figure 1 ), and hydrodynamic injections were performed into a specially constructed pressure-resistant reservoir connected to the HydroJector-EM. The actual pressure (black solid lines in Figure 1) , and electromotor output power during the injections (black dotted lines in Figure 1 ) showed precise control of pressure and motor power over a short period, and even complex pressure patterns were precisely reproduced, suggesting a high level of controllability of the HydroJector-EM. This controllability of pressure during injection is important for reproducibility of an injection, as well as for safety in future human gene therapy, because it avoids unexpected too high pressure.
Pressure controllability of the HydroJector-EM in vivo To examine whether the HydroJector-EM could reproduce the injection controllability in vivo, HGD was performed in rat livers using a catheter-based procedure ( Figure 2 ). An injection catheter was inserted into the IVC and another catheter was placed in the PV close to the liver and was connected to a pressure sensor, which sent actual intrahepatic pressures to the programmed computer controlling the HydroJector-EM (Figure 2a ). Using the same HydroJector-EM settings and various preloaded exponential time-pressure curves optimized in vitro (see Identification of the ideal time-pressure curves under Materials and methods section), pCMV-Luc plasmid solution in saline (5 mg ml (Figure 2c ). The peak pressure achieved showed o5% delineation from the preloaded curves (for pressure i, actual pressure achieved 0.7 mm Hg higher than the preloaded 15 mm Hg), and the differences in injection volume between each animal injected with the same timepressure curve were o0.47% BW (Figure 2d ). These data support the high controllability of the HydroJector-EM in vivo using catheter-based procedure, resulting in reproducible hydrodynamic injection by replicating the time-pressure curves.
Efficiency and reproducibility of the HydroJector-EM-mediated gene delivery The above time-pressure curves, using a manual injection method as a control, were completed safely, and liver, heart, lung and kidney tissues were harvested 3 h after the injections. The injection volume and time period for manual injection was set to be the same as curve iii with sustained injection flow rate showing a simple linear proportional time-pressure curve. The highest level of luciferase expression of 272 pg luciferase per mg of extracted proteins was obtained with pressure curve iii. This was 2-20 times higher than the levels achieved with pressure curves i, ii and iv, and with manual injection (Po0.05 for 'manual vs iii', but Po0.01 for 'iv vs iii' and Po0.001 for 'ii vs iii' and 'iv vs iii'; Figure 3a ). No luciferase activity was detected in the heart, lung and kidneys (data not shown). Immunohistochemical staining using an anti-luciferase antibody was performed on livers collected 3 h after injection with pressure curves (Figures 3b-g ). The largest number of the positively stained cells, 12.6%, was obtained with pressure curve iii, and was significantly 2.6-10 times higher than the levels achieved with pressure curves i, ii and iv (Po0.001 for 'i vs iii', 'ii vs iii' and 'iv vs iii'; Figure 3h ). The level was not significantly different from the 10% positive cells obtained with manual injection (Figure 3h ). These results suggest efficient and reproducible gene delivery by the HydroJector-EM and that pressure curve iii, which injects with a higher pressure over a shorter period, resulting in a more efficient gene delivery.
Physiological impacts
To examine the safety of our system, hematoxylin and eosin staining on the liver tissue and serum biochemical analysis were performed. The pressure curve iii injection, which achieved highest pressure over the shortest time among those tested, was compared with manual injection. Hematoxylin and eosin staining was performed on the liver tissues before (Figure 4a ), immediately after (Figures 4b, c ) and 3 h after (Figures 4d, e) the HydroJector-EM controlled injection with preloaded time-presure curve iii (Figures 4b, d ) and manual injection (Figures 4c, e) . There was a marked enlargement of the central veins and sinusoidal structure immediately following the injections (Figures 4b, c) , and there were no marked differences between the injections. These enlargements recovered by 3 h post-injection, and no marked destruction of hepatocytes or necrotic tissues were seen 7 days after the injection (Figure 4f ).
Blood samples were collected from the catheter placed in the IVC at the same time points as for the hematoxylin and eosin assays, and markers of liver status, including aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) in the serum, were analyzed to assess tissue damage after injection with pressure curve iii and manual injection (Figures 4g, h) . AST, ALT and LDH showed peak levels of 1418, 911 and 6671 IU ml À 1 , respectively, 1 h after injection with pressure curve iii and 1228, 932 and 9065 IU ml À 1 , respectively, 1 h after manual injection. These levels returned to normal 7 days after both injections, and no significant differences were seen. These results suggest that there are no significant differences in the physiological impact of computer-controlled and manual injections. These results also indicate that the HydroJector-EM can achieve efficient, reproducible and safe gene delivery in vivo. Figure 1 . Development of the HydroJector-EM. Various time-pressure curves can be preloaded to the programmed computer. The electric power-driven injector injects a solution hydrodynamically by pushing the sterilized syringe. The actual pressure in the target during the injection is transmitted to the programmed computer every 0.05 s upon the injection through a sensor and amplifier. According to the actual pressure, the programmed computer controls the output electric-injection power moving to reproduce this preloaded pressure in the target region (a). Assessment of the controllability of the HydroJector-EM in vitro using a pressure-resistant reservoir connected to the HydroJector-EM (b-e). The exponential (b), convex (c), stepwise (d) and frequent spike (e) time-pressure patterns were preloaded to the system and tested for the reproducibility. Gray solid lines, black solid lines and black dotted lines represent time-dependent preloaded pressure, actual in vitro pressure and relative electromotor output power to its capacity, respectively.
Long-term gene expression study Based on the above results, the pBS-HCRHP-FIXIA plasmid was hydrodynamically injected into rats using the HydroJector-EM, to examine the reproducibility of sustained gene expression. Pressure curve iii, which resulted in the highest gene delivery efficiency in the previous section, was utilized for the study, and the serum level of human factor IX was analyzed by enzymelinked immunosorbent assay for 112 days. Additionally, injection using pressure curve i reaching 15 mm Hg and manual injection of 6% BW were tested for the same period. Human factor IX achieved its highest level of 5390±474 ng ml À 1 7 days after injection with pressure curve iii. This was 17-fold higher than the level achieved with pressure curve i (317 ± 37 ng ml À 1 ; Po0.001) and 2.7-fold higher than the level achieved by manual injection (2030 ± 374 ng ml À 1 ; Po0.01). Human factor IX slowly decreased to the background level by 80 days after injection. Immunohistochemical staining using anti-human factor IX antibody was performed to confirm the results. Positively stained hepatocytes were detected 7 days after the injections ( Figure 5 , black arrows). Pressure curve iii injection resulted in 9.7% positively stained cells in four different sections (Figure 5d ), whereas manual injection ( Figure 5e ) and injection with curve i (Figure 5c ) resulted in 7.4% and 5.5% positive cells, respectively, while no stained cells were seen in saline-injected rats liver (Figure 5b ). In addition, the level returned to this control level 112 days after the injection. Altogether, these data suggest that the HydroJector-EM gene transfer protocol can deliver plasmids safely and efficiently, and achieve a therapeutic level of human factor IX protein (4500 ng ml À 1 ) sustained for 2 months.
DISCUSSION
The list of applications for gene therapy is growing rapidly, including cancer, heart disease and hemophilia. 1 Among the various gene delivery methods, HGD is relatively new, 7 having first been reported by Liu et al. 2 and Zhang et al. 3 in 1999 as a simple and efficient gene delivery method through the tail veins of small animals. The key aspects for successful HGD include injection power, intravascular pressure, volume, speed and time period. [9] [10] [11] [12] Various modifications have been made to the original procedure to apply this method to human gene therapy. The catheter-based procedure contributed to the reduction of injection volume [13] [14] [15] [16] [17] [18] [19] and the CO 2 -pressurized injection device, the HydroJector, maintained injection parameters, such as sustained injection power, volume, speed and period for examining the optimum parameters for gene delivery efficiency and safety in large animals. 20 We have proven that the combination of these developments have achieved liver lobe-and target musclespecific gene delivery in large animal and called 'Image-guided regional HGD'. 17, 18 To further extend the clinical applicability of our technology, we have focused on the gene injection timeintravascular pressure curves to ensure the reproducibility and controllability of gene delivery in this study and developed a new electric power-driven injector, the HydroJector-EM. We have demonstrated that: (1) it can precisely replicate the timepressure curves preloaded into the system before HGD in animals and ensure reproducible gene delivery to various targets by flexibly changing the electric-injection power; (2) it consists of clinically approved parts and disposable products; and (3) it utilizes electric power as a physical force for HGD rather than the CO 2 gas used in previous studies, thereby reducing the risk of gas embolism (although this small amount of CO 2 gas is also used for phase contrast in angiography with patients who have allergies to contrast enhancements).
The HydroJector-EM showed efficient gene delivery with timepressure curve iii reaching 30 mm Hg in 10 s, which was the highest pressure over the shortest period among tested. The level of luciferase expression was higher than the manual injection utilizing the same volume and period, probably due to the difference in pressure-time curves, 'exponential' with iii and simple 'linear proportional line' with fixed flow rate manual injection. However, the manual injection also achieved the therapeutic level of hFIX, although lower level than curve iii, the proximity of the efficacy of both procedures was revealed. The significant advantage of our injector and the difference from the manual injection is that the reproducibility of our injection showing the less variability of gene expression in animals (Supplementary Figure S1) . Since the gene delivery efficiency by the sustained flow rate injection by manual or single pump was affected by the possible leakage due to the intravenous anastomosis in large animals and the high intravascular pressure due to the species specific structure of target organ tissue, such as fibrotic tissue in pigs liver, this reproducibility achieved by the HydroJector-EM, that flexibly control the injection power, will exceed these matters and be efficient in the gene delivery in various large animals because the injection power changes according to the actual intravascular pressure upon the injection. The serum levels of AST, ALT and LDH reached peak in 1 h after the injection as reported previously, 12 with a traditional tail vein injection of 7.5% BW volume. The level was 10-fold higher than that achieved by the tail vein injection, 12 probably due to the difference in injection site since our catheter-based procedure directly injects to the whole liver with temporal blood flow occlusion at IVC to reduce the injection volume.
Our long-term study showed a promising therapeutic level of hFIX expression that was sustained for more than 2 months. The level achieved was comparable to the results shown in previous studies by Miao's group [21] [22] [23] using mouse tail vein injection and ultrasound. For hemophilia gene therapy, a number of studies, especially those using an adeno-associated virus vector, have shown therapeutic and sustained hFIX expression in animals (for recent reviews, see Tuddenham 24 and Benveniste 25 ). Interestingly, Brunetti-Pierri et al. 26 utilized a catheter-based procedure for helper-dependent adenoviral vector transfer to the monkey liver and showed increased liver-specific transduction showing therapeutic level of gene expression with reduced systemic vector dissemination, suggesting the importance of a catheterbased procedure. While viral vectors are highly effective and have been used in quite a few clinical trials, the intrinsic carcinogenesisand immune-response-stimulating properties of viral genomes and proteins remain the largest hurdle, and the injection of plasmid DNA is considered to be safer. 7 Therefore, the results obtained in this study suggest a promising option for hemophilia gene therapy, as the automatic-injector delivery of simple naked DNA achieved a therapeutic level that has never before been seen in rats. The slow decrease to the background level by 80 days after injection was probably due to factors, such as methylation of plasmid, 27 antibody to the human factor IX. 28 In addition, the reproducible gene delivery efficiency based on the intravascular time-pressure curve may enable us to estimate the therapeutic effect upon gene delivery, and this new system suggests versatile applications, including combining with virus vector and protein delivery, among other possibilities. 9, 20 In summary, we have reported on the development and effectiveness of the HydroJector-EM. We have confirmed its reproducibility and controllability for gene delivery and long-term therapeutic gene expression. An assessment of its effectiveness in large animals, organs and disease models combined with a catheter-based procedure will be the next logical steps toward clinical applications. The fine-tuning of the procedure and plasmid engineering is also a necessary prerequisite for clinical trials of HGD.
MATERIALS AND METHODS Materials
The pCMV-Luc plasmid containing firefly luciferase cDNA driven by a CMV promoter was purified by the method of CsCl-ethidium bromide gradient centrifugation and kept in a Tris-EDTA buffer. The pBS-HCRHP-FIXIA plasmid containing human factor IX gene driven by hAAT promoter was kindly provided by Dr Carl Miao's lab. 22 The purity of the plasmid preparation was checked by absorbency at 260 and 280 nm and 1% agarose gel electrophoresis. The luciferase assay kit was from Wako Pure Chemical Industries Ltd (Chuo-ku, Osaka, Japan). The electric power-driven motor for the injector was from Tsugawa EW Co. Ltd (Nishinari-ku, Osaka, Japan). The pressure transducer was from Kyowa Electronic Instruments Co. Ltd (Chofu, Tokyo, Japan). The charger amplifier unit AG3101 was from NEC Avio Infrated Technologies Co. Ltd (Shinagawa-ku, Tokyo, Japan). Wistar rats (female, 150-200 g) were purchased from Japan SLC Inc. (Hamamatsu, Shizuoka, Japan).
Hydrodynamic injection into rat liver
All animal experiments were conducted in full compliance with regulation and approved by the Institutional Animal Care and Use Committee at the Niigata University (Niigata, Japan). A midline skin incision was made under general anesthesia using isoflurane and 2,2,2-tribromoethanol (concentration, 0.016 g ml À 1 in 0.9% saline; dose, 1.25 ml/100 g BW). With a small incision in the abdominal wall, an injection catheter (SURFLO 22 gauge; Terumo, Sibuya-ku, Tokyo, Japan) was inserted via the IVC and its tip placed at the junction of the IVC and the hepatic veins. A pressure transducer was connected to another catheter (SURFLO 20 gauge; Terumo) placed in the PV in hepatic hilar side, which reflected the intrahepatic sinusoidal pressure upon the injection. 29 Saline containing either pCMVLuc or pBS-HCRHP-FIXIA plasmid DNA (5 mg ml À 1 ) was injected into the liver via the HydroJector-EM under the program with temporal blood flow occlusions at the supra-and infrahepatic IVC as used in small animals 20 and in non-human primates. 26, 30 The incision made at the animals' abdomen was sutured after the procedure.
Identification of the ideal time-pressure curves HGD was performed in rats with different settings of preloaded exponential time-pressure curves. Among the various pressure curves tested in vitro shown in Figure 1 , exponential curves with a peak pressure of 15 and 30 mm Hg and injection period of 10 and 20 s were chosen for the gene delivery analysis since the other curves with higher pressure and longer period showed intolerableness in rats cardiovascular condition.
Manual injection procedure
To examine the safety and efficiency of the HydroJector-EM controlled injections, the steady manual injection of 6% BW, the same volume as used in pressure curve iii (5.5±0.47%) in 10 s was performed.
Luciferase assay HGD of pCMV-Luc plasmid DNA was performed with different settings of preloaded time-pressure curves. The rat was euthanized 3 h after the injection of pCMV-Luc plasmid DNA and tissue samples were collected from each lobe of the liver, kidney, lung and heart. Tissue samples for the luciferase assay were kept in -80 1C until use. A measure of 1 ml of lysis buffer (0.1 M Tris-HCl, 2 mM EDTA and 0.1% Triton X-100, pH 7.8) was added to each sample (B200 mg) and the samples were homogenized for 30 s with the tissue homogenizer (ULTRA-TURRAX T25 Digital; IKA, Staufen, Germany) at maximum speed. The tissue homogenates were centrifuged in a microcentrifuge for 10 min at 13 000 g at 4 1C. The protein concentration of the supernatant was determined by Protein Assay Kit (Bio-Rad, Hercules, CA, USA) based on Coomassie blue assay strategy. A measure of 10 ml of supernatant was mixed with 100 ml of luciferase assay reagent and the luciferase activity was measured in a luminometer (Luminescencer Octa AB-2270; Atto, Bunkyo-ku, Tokyo, Japan) for 10 s according to the previously established procedure. 2 Luciferase activity obtained as the relative light units was converted to luciferase mass using standard curve established using reagents and procedure from Analytic Luminescence Laboratory (San Diego, CA, USA). 2 The amount of luciferase protein in the tissue extract was calculated using the equation derived from the standard curve in which luciferase protein (pg) ¼ 7.98 Â 10 À 5 RLU þ 0.093 (R 2 ¼ 0.9999).
Analysis of serum hFIX concentration
Animals were hydrodynamically injected with the pBS-HCRHP-FIXIA plasmid or saline. Blood samples were collected from their tail vein before, 4, 7, 14, 28, 56, 84 and 112 days after the gene delivery according to the preliminary data and plasma were collected for enzyme-linked immunosorbent assay. A mouse anti-hFIX monoclonal antibody (clone HIX-1, F2645l Sigma, St Louis, MO, USA) was used for plate coating, and the horse radish peroxidase-conjugated goat anti-hFIX polyclonal antibody (GAFIX-HRP; Affinity Biologicals, Ancaster, ON, Canada) was used as the second antibody for binding to hFIX that bound to the well.
Immunohistochemical stainings
Tissue samples for immunohistochemical stainings were collected 3 h after the injection for luciferase staining and 7 and 112 days after for hFIX staining. Four different liver sections from three rats in each group and untreated rats were immunohistochemically stained with anti-luciferase antibody or anti-hFIX antibody. Tissues were fixed in 10% formalin upon the collection and embedded in paraffin. Sections (10 mm) were made and standard immunohistochemistry was performed with a goat anti-luciferase polyclonal antibody (G7451, 1:50 dilution; Promega, Madison, WI, USA), Vecstatin Elite ABC Goat IgG Kit (PK-6105; Vector Laboratories Inc., Burlingame, CA, USA) and DAB chromogen tablet (Muto Pure Chemicals Co. Ltd, Bunkyo-ku, Tokyo, Japan) for luciferase staining. The rabbit antihFIX polyclonal antibody (HPA 000254, 1:100 dilution; Sigma), Vecstatin Elite ABC Rabbit IgG Kit (PK-6101; Vector Laboratories Inc.), and DAB chromogen tablet (Muto Pure Chemicals Co. Ltd) were used for hFIX staining. Every three fields from each section (total of 36 fields for each curves and control) were captured and a quantitative analysis of positively stained cells was performed using the ImageJ software (version 1.6.0_20; National Institutes of Health, Bethesda, MD, USA) as previously reported method. 31 
Assessment of tissue damages
The blood samples were collected at the appropriate time points as in the previous study, 12 which were before (time ¼ 0), 2 min, 1 h and 3 h after the hydrodynamic injection of pCMV-Luc from seven animals and additional data points before, 2 min and 7 days after the injection were collected from nine rats hydrodynamically injected with pBS-HCRHP-FIXIA. Automated concentration determination of ALT, AST and LDH was performed by BML
